The current financial score of Aquestive Therapeutics Inc is 8.21. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 13.82M, representing a year-over-year increase of 38.15%, while its net profit experienced a year-over-year increase of 68.76%.
The current valuation score of Aquestive Therapeutics Inc is 8.79. Its current P/E ratio is -7.57, which is -91.42% below the recent high of -0.65 and -526.35% above the recent low of -47.40.
The current earnings forecast score of Aquestive Therapeutics Inc is 8.44. The average price target is 9.33, with a high of 11.00 and a low of 6.00.
The current price momentum score of Aquestive Therapeutics Inc is 4.54. Currently, the stock price is trading between the resistance level at 5.22 and the support level at 4.25, making it suitable for range-bound swing trading.
The current institutional shareholding score of Aquestive Therapeutics Inc is 5.00. The latest institutional shareholding proportion is 60.30%, representing a quarter-over-quarter increase of 16.73%. The largest institutional shareholder is James Simons, holding a total of 416.25K shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.
The current risk assessment score of Aquestive Therapeutics Inc is 5.26. The company's beta value is 1.48. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.